“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.
In this video, Benjamin Lowentritt, MD, FACS, shares his thoughts on the pivotal study, “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Lowentritt is the director of minimally invasive surgery and robotics and the director of the Prostate Cancer Care Program at Chesapeake Urology in Baltimore, Maryland.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
2 Clarke Drive
Cranbury, NJ 08512